US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs
US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1
LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption
HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2026, which ended on December 31, 2025. All figures are in Canadian dollars unless otherwise stated.
“During the past quarter, we made important progress in advancing multiple U.S. federal funding proposals that, if awarded, could meaningfully support our key pipeline and collaborator programs.” said Dr. Don Cilla, President and CEO of Appili. “With the recent award up to US $40 million for VXV-01 and continued access to non-dilutive capital, Appili is steadily strengthening its funding base to drive infectious disease assets forward.”
Non-Dilutive Government Funding Model Delivering Results
Appili continues to leverage strategic government partnerships to advance its infectious disease and biodefense pipeline. The Company has secured over US$75 million in cumulative government funding since inception and has an additional US$82 million in proposals in active review across multiple programs. Non-dilutive funding sources enable Appili to advance critical development activities, including manufacturing, preclinical studies, regulatory activities, and clinical trial preparation and conduct, while preserving shareholder value.
ATI-1801 – Topical Antiparasitic Program with an Aligned Regulatory Path
Following positive feedback from the U.S. Food and Drug Administration (“FDA”) on its scientific bridging strategy, ATI-1801, a topical formulation of paromomycin for cutaneous leishmaniasis has a clearly defined registration pathway to support an NDA submission. Appili is actively pursuing non-dilutive funding from global health organizations and government agencies that share the Company’s focus on tropical diseases to execute this strategy and complete the remaining development work.
Appili’s ATI-1801 is potentially eligible to receive a Priority Review Voucher (“PRV”) upon FDA approval, which is anticipated as early as the fourth quarter of 2029 subject to securing the requisite funding. Recent PRV transactions have reached US$200 million, representing meaningful non-dilutive value creation
LIKMEZ® (ATI-1501), Commercial Momentum Building in U.S. Market
Saptalis Pharmaceuticals, Appili’s manufacturing and commercialization partner, continues to commercialize LIKMEZ (metronidazole oral suspension, 500 mg/5 mL), the first and only FDA-approved liquid oral formulation of metronidazole. Since the re-launch in May 2025, LIKMEZ has demonstrated steady sales growth, reflecting strong clinician and patient demand.
Under the agreement with Saptalis, Appili is eligible to receive sales-based milestone payments and royalties, providing a growing source of commercial revenue. In April 2025, additional patents protecting LIKMEZ’s composition and preparation methods were published in the …